Logo

OPSUMIT® ist eine Grundlage für die Behandlung der pulmonalen arteriellen Hypertonie (PAH) und wird zur Erstlinienbehandlung als Monotherapie sowie im Rahmen einer Kombinationstherapie empfohlen.[1][2] Die Wirksamkeit von OPSUMIT® ist aus den Studien SERAPHIN, OPTIMA und REPAIR belegt.[2][3][4][5]

Component not published? componentType is undefined.

Component not published? componentType is undefined.

Component not published? componentType is undefined.

0

PAH, pulmonale arterielle Hypertonie

Component not published? componentType is undefined.

0

Références

Galiè N, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37(1):67-119.
Pulido T, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369(9):809-18.
Pulido T, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369(9):809-18 (supplementary appendix).
Sitbon O, et al. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J 2020;56(3):2000673.
Vonk Noordegraaf A, et al. The REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging 2021;6:S1936-878X(21)00635-5.